80 results
PRE 14A
IMUX
Immunic Inc
24 Jan 24
Preliminary proxy
5:05pm
Awards pending any investigation of the matter.
18.6 No Rights as a Stockholder. No Grantee shall have any rights as a stockholder of the Company
8-K
EX-10.1
IMUX
Immunic Inc
5 Jan 24
Immunic, Inc. Announces Private Placement of up to $240 Million
6:41am
investigation that would reasonably be expected to lead to such a claim.
4.16. Legal Proceedings. Except as disclosed in the SEC Filings, there are no legal … such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect such Investor’s right
S-8
EX-4.2
5cmchemkpk 731
21 Aug 23
Registration of securities for employees
6:30am
8-K
EX-99.1
yjyn1ooe7sxo6ou0 r5v
20 Oct 22
Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate
4:32pm
8-K
EX-10.1
h8m8 4oc9aq1m7f
11 Oct 22
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
8:30am
8-K
EX-4.1
yhucmo t9m0rwg
11 Oct 22
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
8:30am
8-K
EX-99.1
r74qviajo 9s9j8uu
20 Sep 22
Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects
8:04am
8-K
EX-10.1
2x1490a5lfu1pxun
2 May 22
Entry into a Material Definitive Agreement
8:06am
8-K
EX-99.1
m74tenkx
14 Dec 21
Other Events
8:20am
8-K
EX-1.1
zplh7d
19 Jul 21
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
lla38
26 Feb 21
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
6:53am
8-K
EX-99.3
lbf4rpwzobcluiruki4x
18 Feb 21
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
7:40am
8-K
EX-10.1
2171wz7evvo699a
4 Jan 21
Entry into a Material Definitive Agreement
6:03am